Semler Scientific (OTCMKTS:SMLR) and Biosig Technologies (NASDAQ:BSGM) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk.

Insider & Institutional Ownership

9.6% of Semler Scientific shares are owned by institutional investors. Comparatively, 2.5% of Biosig Technologies shares are owned by institutional investors. 13.9% of Semler Scientific shares are owned by company insiders. Comparatively, 26.7% of Biosig Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Semler Scientific and Biosig Technologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Semler Scientific 19.66% -982.53% 74.53%
Biosig Technologies N/A -1,112.54% -435.24%

Risk and Volatility

Semler Scientific has a beta of 0.42, suggesting that its share price is 58% less volatile than the S&P 500. Comparatively, Biosig Technologies has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500.

Valuation & Earnings

This table compares Semler Scientific and Biosig Technologies’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Semler Scientific $12.45 million 20.37 -$1.51 million ($0.28) -143.21
Biosig Technologies N/A N/A -$12.69 million N/A N/A

Semler Scientific has higher revenue and earnings than Biosig Technologies.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Semler Scientific and Biosig Technologies, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Semler Scientific 0 0 2 0 3.00
Biosig Technologies 0 0 1 0 3.00

Semler Scientific currently has a consensus price target of $44.00, suggesting a potential upside of 9.73%. Biosig Technologies has a consensus price target of $14.00, suggesting a potential upside of 229.41%. Given Biosig Technologies’ higher probable upside, analysts clearly believe Biosig Technologies is more favorable than Semler Scientific.

Summary

Semler Scientific beats Biosig Technologies on 7 of the 10 factors compared between the two stocks.

Semler Scientific Company Profile

Semler Scientific, Inc. develops, manufactures, and markets patented products that assist healthcare providers to evaluate and treat patients with chronic diseases in the United States. Its products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition; and WellChec, a multi-test service platform to evaluate patients with various chronic diseases. The company's products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, and family practitioners, as well as organizations, including healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry; and other healthcare organizations, such as risk assessment groups and other home healthcare providers. It offers its products through salespersons and distributors. Semler Scientific, Inc. was founded in 2007 and is headquartered in San Jose, California.

Biosig Technologies Company Profile

BioSig Technologies, Inc., a development stage medical device company, engages in developing a proprietary biomedical signal processing technology platform to extract information from physiologic signals. Its product is PURE (Precise Uninterrupted Real-time evaluation of Electrograms) EP System, a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes, and displays electrocardiogram and electrograms required during electrophysiology studies and catheter ablation procedures. It is also developing a library of software tools that are designed to be configured to fit the needs of electrophysiologists in various settings and for arrhythmia treatments. The company was founded in 2009 and is headquartered in Los Angeles, California.

Receive News & Ratings for Semler Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Semler Scientific and related companies with MarketBeat.com's FREE daily email newsletter.